Radiotherapy plus QL1706 and Bevacizumab for unresectable liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2, open-label, randomized trial enrolling 60 adults with unresectable, non-metastatic hepatocellular carcinoma. Participants are assigned to receive either radiotherapy with immunotherapy and bevacizumab or immunotherapy with bevacizumab alone. The study aims to compare tumor response and the rate at which patients become eligible for surgery between the two groups. Safety and tolerability will be monitored throughout the treatment period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Age ≥ 18 years old, gender not limited; PS score 0-2; Pathologically or clinically diagnosed as primary HCC and has not received other anti-HCC treatment; No history of other malignant tumors or treatment; Patients with BCLC stage B or C before treatment and no distant metastasis, and surgical assessment indicates that first-line surgical resection is not feasible; Liver function grade Child-Pugh A or B ≤ 7 points; For patients with active HBV infection, antiviral treatment should be initiated at least 7 days before treatment and they should agree to continue antiviral treatment during the study period; No severe cardiovascular or cerebrovascular diseases; Women of childbearing age should agree to use contraceptive measures (such as intrauterine devices, contraceptives or condoms) during the treatment period and 6 months after treatment; if the serum or urine pregnancy test is negative within 14 days before inclusion in the study, and the patient must be non-lactating; men should agree to take contraceptive measures during the study period and 6 months after the study; Voluntarily sign the written informed consent form and commit to comply with the protocol during the study period, including accepting treatment and scheduled visits and examinations, including follow-up; The expected survival must be at least 12 weeks.

Exclusion Criteria:

Patients who do not meet the above main inclusion criteria; Patients who refuse to sign the informed consent form; Patients with pathological types of cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, mixed cell carcinoma and fibrolamellar cell carcinoma; or those with postoperative pathology suggesting metastatic cancer or primary cancer of other tissue types; Patients with portal hypertension diagnosed by preoperative enhanced abdominal CT and endoscopy, with a history of esophageal variceal bleeding, severe hypersplenism syndrome or refractory ascites; Patients diagnosed with severe active scleroderma, lupus, other rheumatic diseases or autoimmune diseases within the past 3 months before study recruitment; patients with a history of clinically severe autoimmune diseases or those requiring systemic steroids or immunosuppressants will not be allowed to participate in this study; Patients with a history of cognitive dysfunction or mental illness that affects treatment compliance; Patients whom the investigator deems unsuitable for participation in this study.

Where it's running

• Hebei Medical University Fourth Hospital
  Shijiazhuang, Hebei, China Recruiting

Study contacts

• Study coordinator: Fengpeng Wu
• Email: wfpzhj@126.com
• Phone: 86-031186296771

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HAIC vs. TACE plus sintilimab and bevacizumab for intermediate HCC with high tumor burden

  This trial tests whether FOLFOX-HAIC plus immunotherapy and anti-angiogenic therapy works better than TACE plus the same systemic therapy for adults with intermediate-stage hepatocellular carcinoma with tumors beyond Up-To-Seven criteria.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07594340

• Sintilimab plus bevacizumab biosimilar before surgery for resectable liver cancer

  This trial will test whether giving sintilimab together with a bevacizumab biosimilar before surgery helps people with resectable hepatocellular carcinoma beyond the Milan criteria.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07324824

• Carbon ion radiotherapy plus atezolizumab and bevacizumab for advanced hepatocellular carcinoma

  This trial will try adding carbon ion radiotherapy to standard atezolizumab‑bevacizumab treatment for adults with advanced hepatocellular carcinoma to see if it controls tumors better and improves survival.

  Recruiting Phase 2 Yonsei University · Seoul · NCT07246668

• HAIC plus iparomlimab or tuvonralimab with bevacizumab, followed by SBRT for advanced liver cancer with portal vein involvement or limited metastases

  This trial will test whether giving hepatic artery infusion chemotherapy with an immune checkpoint antibody (iparomlimab or tuvonralimab) plus bevacizumab, followed by focused stereotactic radiation, helps people with advanced hepatocellular carcinoma that involves the portal vein or has a small number of metastases.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07062055

• Combining atezolizumab and bevacizumab with Y-90 radioembolization to help people with liver cancer get to transplant

  This trial tests whether adding immunotherapy (atezolizumab plus bevacizumab) to Y-90 radioembolization can help people with hepatocellular carcinoma bridge to or be downstaged for liver transplant.

  Recruiting Phase 4 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07059494

• Rilvegostomig plus bevacizumab, with or without tremelimumab, versus atezolizumab plus bevacizumab for advanced liver cancer

  This trial tests whether rilvegostomig combined with bevacizumab, with or without tremelimumab, works better than atezolizumab plus bevacizumab as first-line treatment for people with advanced hepatocellular carcinoma who are not candidates for curative or locoregional therapy.

  Recruiting at 189 sites Phase 3 AstraZeneca · Phoenix, Arizona and 225 other locations · NCT06921785

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.